216 related articles for article (PubMed ID: 37524205)
21. Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer.
Hartl CA; Bertschi A; Puerto RB; Andresen C; Cheney EM; Mittendorf EA; Guerriero JL; Goldberg MS
J Immunother Cancer; 2019 Jul; 7(1):199. PubMed ID: 31362778
[TBL] [Abstract][Full Text] [Related]
22. [The meaning of PD-1/PD-L1 pathway in ovarian cancer pathogenesis].
Piętak P; Pietrzyk N; Pawłowska A; Suszczyk D; Bednarek W; Kotarski J; Wertel I
Wiad Lek; 2018; 71(5):1089-1094. PubMed ID: 30176647
[TBL] [Abstract][Full Text] [Related]
23. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.
Setordzi P; Chang X; Liu Z; Wu Y; Zuo D
Eur J Pharmacol; 2021 Mar; 895():173867. PubMed ID: 33460617
[TBL] [Abstract][Full Text] [Related]
24. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
25. PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way.
Yu X; Long Y; Chen B; Tong Y; Shan M; Jia X; Hu C; Liu M; Zhou J; Tang F; Lu H; Chen R; Xu P; Huang W; Ren J; Wan Y; Sun J; Li J; Jin G; Gong L
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253000
[TBL] [Abstract][Full Text] [Related]
26. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
27. Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment.
Gulley JL; Schlom J; Barcellos-Hoff MH; Wang XJ; Seoane J; Audhuy F; Lan Y; Dussault I; Moustakas A
Mol Oncol; 2022 Jun; 16(11):2117-2134. PubMed ID: 34854206
[TBL] [Abstract][Full Text] [Related]
28. Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy.
Yanik EL; Kaunitz GJ; Cottrell TR; Succaria F; McMiller TL; Ascierto ML; Esandrio J; Xu H; Ogurtsova A; Cornish T; Lipson EJ; Topalian SL; Engels EA; Taube JM
JAMA Oncol; 2017 Jul; 3(7):974-978. PubMed ID: 28334399
[TBL] [Abstract][Full Text] [Related]
29. Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.
Tai YT; Cho SF; Anderson KC
Front Immunol; 2018; 9():1822. PubMed ID: 30147691
[TBL] [Abstract][Full Text] [Related]
30. Expression of PD-L1 in ovarian cancer and its synergistic antitumor effect with PARP inhibitor.
Xue C; Xu Y; Ye W; Xie Q; Gao H; Xu B; Zhang D; Jiang J
Gynecol Oncol; 2020 Apr; 157(1):222-233. PubMed ID: 31987601
[TBL] [Abstract][Full Text] [Related]
31. Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.
Wu M; Huang Q; Xie Y; Wu X; Ma H; Zhang Y; Xia Y
J Hematol Oncol; 2022 Mar; 15(1):24. PubMed ID: 35279217
[TBL] [Abstract][Full Text] [Related]
32. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues.
Hamanishi J; Mandai M; Matsumura N; Abiko K; Baba T; Konishi I
Int J Clin Oncol; 2016 Jun; 21(3):462-73. PubMed ID: 26899259
[TBL] [Abstract][Full Text] [Related]
33. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
Hayashi H; Nakagawa K
Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies.
Antonia SJ; Vansteenkiste JF; Moon E
Am Soc Clin Oncol Educ Book; 2016; 35():e450-8. PubMed ID: 27249753
[TBL] [Abstract][Full Text] [Related]
35. Improving the synergistic combination of programmed death-1/programmed death ligand-1 blockade and radiotherapy by targeting the hypoxic tumour microenvironment.
Mudassar F; Shen H; Cook KM; Hau E
J Med Imaging Radiat Oncol; 2022 Jun; 66(4):560-574. PubMed ID: 35466515
[TBL] [Abstract][Full Text] [Related]
36. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.
Zeng Y; Li B; Liang Y; Reeves PM; Qu X; Ran C; Liu Q; Callahan MV; Sluder AE; Gelfand JA; Chen H; Poznansky MC
FASEB J; 2019 May; 33(5):6596-6608. PubMed ID: 30802149
[TBL] [Abstract][Full Text] [Related]
37. Prospective role of PD-1/PD-L1 immune checkpoint inhibitors in GI cancer.
AmeliMojarad M; AmeliMojarad M; Cui X
Pathol Res Pract; 2023 Apr; 244():154338. PubMed ID: 36905697
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
Philips GK; Atkins M
Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
[TBL] [Abstract][Full Text] [Related]
39. Potential and unsolved problems of anti-PD-1/PD-L1 therapy combined with radiotherapy.
Cao Y; Li W; Wang Z; Pang H
Tumori; 2021 Aug; 107(4):282-291. PubMed ID: 32734832
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy for cancer treatment.
Donátová K; Nováková E; Šupolíková M
Klin Onkol; 2022; 35(4):284-289. PubMed ID: 35989085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
